ThermoDox plus RFA Increases Liver Cancer OS by 58 Percent in HEAT Study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The latest overall survival analysis of the HEAT Study, which is evaluating ThermoDox and radiofrequency ablation in hepatocellular carcinoma, showed that a subgroup of patients demonstrated an average 58 percent improvement in overall survival.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login